Introduction oxide (NO) release from endothelial cells associated with the increased levels of an incretin hormone, gastrointestinal peptide (GIP), and increased PV flow (5) . NO is a short-living vasodilator with a significant role in the regulation of the vascular tonus (6) . The effects of vildagliptin on PV pressure and hepatosteatosis were investigated previously (7) . However, a long-term prospective study was not performed. In our study, we aimed to investigate the effects vildagliptin (DPP-4 inhibitor) on portal system pressure and hepatic steatosis by means of laboratory tests and portal system Doppler ultrasonography (US) in patients with type 2 DM following 18-month therapy.
Method
The study was designed as a prospective observational study. The study included patients to whose treatment vildagliptin (2*50 mg) was added while they were on therapy with metformin (2*1000mg), gliclazide (1*60 mg) for type 2 DM (the vildagliptin group). As the control group, patients treated with metformin (2*1000 mg) and gliclazide (1*60 mg) were included (the control group). Complete blood counts (CBCs) and biochemistry tests were performed in all subjects and their demographics were recorded. Each subject's PV diameter, PV flow volumeand PV flow velocity were measured with the same doppler US device and by the same radiologist to evaluate PV pressure . Hepatic steatosis was also graded with US during the same session. Both the vildagliptin group and the control group were followed up for a period of 18 months and subjects who were still on the same treatment at the end of 18 months and who did not meet the exclusion criteria underwent repeat PV doppler US. These subjects' CBCs and biochemistry tests were also repeated and demographics were recorded again. Of these subjects, vildagliptin users were evaluated in the pre-treatment and post-treatment periods. The subjects in the control group who did not receive vildagliptin were evaluated in the pretreatment and post-treatment periods. The obtained results were compared at the end of the study.
The study included patients who were at least 18 years of age, treated with gliclazide and metformin only or with vildagliptin added to gliclazide and metformin therapy. Patients with chronic liver disease which may increase portal pressure, congestive heart failure, chronic renal failure, chronic obstructive pulmonary disease, vasculitis and active infectious disease were excluded. In addition, patients receiving agents that are known to act on portal pressure including beta-blockers and isosorbide mononitrate were also excluded. Further exclusion criteria included patients treated with agents that are known to induce NO release including angiotensin converting enzyme blockers, angiotensin receptor blockers, calcium channel blockers. The study was initiated after it was approved by both the Ministry of Health and Ethics Board of Bezmialem Vakif University. Doppler US method: The patients were instructed to fast after midnight and the analysis was performed between 09-12 a.m. Logiq 9 (GE, Milwaukee, USA) US and 3.5 mHz convex probe were used for the analysis when the patient was lying on left lateral decubitus position. First, all liver segments were examined on gray scale and presence and degree of hepatosteatosis were recorded. PV measurements were performed on portal confluence. Doppler degree was maintained at 30°-60°. Appropriate Doppler gain and filter adjustments were made. PV spectrum was recorded for at least 5 seconds mid-inspiration and measurements were made over this wave pattern. PV diameter, flow pattern, flow velocity and flow volume were assessed. These parameters were measured three times for each patient and the mean of measurements was taken.
Venous blood samples were obtained from the patients at least 10-12 hours of fasting. Patients' blood samples were used to measure the following laboratory values: HbA1c (turbidimetric inhibition immunoassay; Roche), low-density lipoprotein cholesterol (LDL-C), triglyceride, hemogram, and alanine aminotransferase (ALT) and creatinine values (immunoassay chemiluminescent method; Beckman Coulter, Pasadena, CA, USA).
Statistical Analysis
SPSS (Statistical Package for Social Sciences) for Windows 15.0 software was used in statistical analyses.
During the assessment of study findings, Student's t-test and paired-samples t test were used to compare parameters with normal distribution. Mann-Whitney U test and Wilcoxon were used to compare parameters without normal distribution. Chi-square and marginal homogeneity tests were employed to compare the proportional data. A two-sided p value of <0.05 was considered significant.
Results
The study was initiated with 48 patients with type 2 DM in the vildagliptin group. After 18 months of follow-up, and the study was completed with 19 participants, 5 of whom were male. On the other hand, the control group including the subjects who did not receive vildagliptin started the study with 49 patients with type 2 DM. This group completed the study with 10 subjects, 5 of whom were male. Demographics and laboratory values of subjects who were treated with vildagliptin did not differ significantly from those of the subjects in the control group. Pre-and post-treatment demographics and laboratory values of subjects in the vildagliptin group were mostly comparable. There was, however, a significant decrease in the creatinine level (p=0.02) and a significant increase in ALT level (p=0.02) ( Table  1) . Pre-and post-treatment values in the control group did not differ significantly (Table 2) .
PV flow velocity, PV flow volume and PV diameter were measured with doppler US in the control and the vildagliptin groups. Comparison of PV parameters in the vildagliptin group demonstrated significant increases in terms of PV flow velocity and PV diameter (p=<0.001, p=0.035, respectively). No significant difference was observed for PV flow volume. In the control group, no significant differences were seen for PV flow velocity or PV flow volume, although there was a significant increase in the PV diameter ( Table 3) . Comparison of 18-month therapy results between the vildagliptin group and the control group demonstrated no significant differences in the PV flow velocity, PV flow volume or diameter (p=0.66, p=0.2, p=0.67, respectively).
Assessment of hepatosteatosis grades did not demonstrate any significant increases in terms of steatosis (p=0.157). There was no significant increase between the control and vildagliptin groups in terms of hepatosteatosis after 18 months of treatment (Table 4 ).
Vildagliptin and control groups' pre-and post-treatment white blood cell, hemoglobin, hemotocrit, mean corpuscular volume and platelet values did not differ significantly (p=0.98, p=0.53, p=0.35, p=0.38, p=0,29, p=39, p=0.94, p=0.7, p=0.27, p=0.7, respectively).
Power analysis calculation of the study based on PV flow velocity yielded a value of 98% in the vildagliptin group.
Discussion
DPP-4 inhibitors are demonstrated to reduce glucose and glucagon levels by increasing serum levels of GLP-1 and GIP hormones. These hormones are known to potentiate NO release by acting on the endothelia in several tissues (6) . It is recognized that elevated levels of NO induce vasodilation in the PV, whereas decreased levels of glucagon are known to cause vasodilation in the splenic vein. In addition to these data, DPP-4 activity was found to be increased in patients with nonalcoholic hepatosteatosis, and hepatosteatosis grade was found to be higher with increasing levels of DPP-4 (8) . Vildagliptin is a DPP-4 inhibitor which is recommended rarely in patients at risk of asymptomatic hepatitis, because its prescribing information advices hepatic function monitoring four times yearly. Based on these data, a decrease in PV pressure and increase in hepatic steatosis may be expected with short-and long-term vildagliptin use. In our study, we intended to investigate these potential effects of vildagliptin using non-invasive methods. Significant increase in PV flow velocity and PV diameter was observed in subjects using vildagliptin in our study. These may be interpreted as a non-invasive indicator of reduced PV pressure (9) . In vildagliptin users, increased PV diameter may be expected as a consequence of increased NO levels. There was no significant decrease in PV flow volume.
Reduced PV flow volume is recognized as an indicator of reduced PV pressure. Cell culture studies showed that exogenous GIP given to dog fetal cell culture increased NO release from PV (4). We could not identify any studies investigating the effect of DPP-4 inhibitors on NO in portal veins. There are, however, many studies on other tissues and organs. In one of these, obese rats were treated with saxagliptin and aortic and glomerular endothelial NO levels were measured. The authors showed significantly elevated endothelial NO levels in animals treated with saxagliptin (10) . Another study demonstrated decreased levels of serum acetyl di-methyl arginine, which is recognized as an indirect indictor of NO elevations, in subjects receiving vildagliptin (11) . These results may be supportive of the results obtained in our study. On the other hand, significantly increased PV diameter in the control group was not, in fact, an expected outcome. Absence of a significant difference in PV flow volume and PV flow velocity may indicate that PV pressure was not significantly affected. Vildagliptin seems to cause a reduction in PV pressure when the results obtained from the vildagliptin group and the control group were taken separately. However, when we compared the 18-month differences of the vildagliptin and control groups, we determined that PV parameters were all comparable between the groups. This contradiction may be explained as follows: although these parameters seemed to differ significantly when assessed in individual groups, the difference, in fact, was very smalland when the whole sample was evaluated, the difference was not significant. These results may suggest that the parameters which allowed indirect estimation of PV pressure were not altered to a significant extent with vildagliptin use.
Patients who completed the 18-month vildagliptin treatment did not differ significantly with regards to hepatosteatosis grade. In the control group, there were no significant differences in hepatosteatosis or serum ALT levels. A published review on the effects of DPP-4s on the liver included studies which reported that DPP-4 inhibitors corrected hepatic steatosis as well as those which described a close association with hepatic steatosis (12) . A study investigating the effects of sitagliptin, a DPP-4 inhibitor, in patients with moderate hepatic impairment found that the drug was safe and did not cause clinical deterioration (13) . Another study reported increased hepatosteatosis with increasing levels of DPP-4 (8) . Our results did not indicate a significant increase in hepatic steatosis.
Another important outcome of the study was that there was a statistically significant decrease in serum creatinine levels in patients receiving vildagliptin versus no significant difference in the creatinine levels in the control group. A previous study found significantly reduced levels of urinary albumin creatinine in subjects who used vildagliptin for 8 weeks compared to controls (14) . Another study demonstrated a significant decrease in creatinine levels in rats treated with vildagliptin (15) . The results of these studies are consistent with the results of our study.
The limitation of our study was that we did not measure the hepatic venous pressure gradient with the invasive angiography, the golden standard of assessing PV pressure. Instead, we preferred portal doppler US which is a non-invasive method and is efficient in determining the severity of portal hypertension. PV flow velocity, diameter and flow volume measured with PV doppler US was reported to have a sensitivity and specificity of 80% in reflecting PV pressure (16, 17) . Another limitation was that a low number of patients completed 18-month treatment in the study.
In conclusion, satisfactory evidence to suggest that vildagliptin use results in a significant decrease in PV pressure was not obtained. However, these results may suggest that vildagliptin does not increase PV pressure. This may be particularly important when selecting an agent for patients with PV pressure. It should also be kept in mind that increased NO release can be dangerous in patients who have esophageal varices or are at risk of having bleeding in esophageal varices. As the second outcome of the study, vildagliptin was not shown to have an effect on hepatosteatosis. This requires larger studies. Further studies are also needed to elucidate whether the obtained results are associated with vildagliptin or are class effects of DPP-4 inhibitors.
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